ReviewEndocrine-related cancer2014
Current views on cell metabolism in SDHx-related pheochromocytoma and paraganglioma.
Review in Endocrine-related cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 35 citations in OpenAlex.
- Altered Expression of Mitochondrial Succinate Dehydrogenase Subunit D Influences Breast Cancer Progression.International journal of molecular sciences · 2026Article
- Malignant carotid body paraganglioma with nodal metastasis: a case report and review of the literature.Journal of medical case reports · 2025Review
- Co-occurrence ofFrontiers in oncology · 2022Article
- A Novel GermlineFrontiers in oncology · 2022Article
- High throughput proteomic and metabolic profiling identified target correction of metabolic abnormalities as a novel therapeutic approach in head and neck paraganglioma.Translational oncology · 2021Article
- Article
- Clinical implications of the oncometabolite succinate in SDHx-mutation carriers.Clinical genetics · 2020Review
- Recent Advances in Histopathological and Molecular Diagnosis in Pheochromocytoma and Paraganglioma: Challenges for Predicting Metastasis in Individual Patients.Frontiers in endocrinology · 2020Review
- Review
- Targeting NADClinical cancer research : an official journal of the American Association for Cancer Research · 2018Article
- Utility of the succinate: Fumarate ratio for assessing SDH dysfunction in different tumor types.Molecular genetics and metabolism reports · 2017Article
- Pheochromocytoma: The First Metabolic Endocrine Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016Review
- Hypoxia potentiates the cytotoxic effect of piperlongumine in pheochromocytoma models.Oncotarget · 2016Article
- Determination of the unmetabolised (18)F-FDG fraction by using an extension of simplified kinetic analysis method: clinical evaluation in paragangliomas.Medical & biological engineering & computing · 2016Article
- Heritable Cancer Syndromes Related to the Hypoxia Pathway.Frontiers in oncology · 2016Review
- Pheochromocytoma: Gasping for Air.Hormones & cancer · 2015Review
- Magnetic resonance spectroscopy of paragangliomas: new insights into in vivo metabolomics.Endocrine-related cancer · 2015Article
- Metabolome profiling by HRMAS NMR spectroscopy of pheochromocytomas and paragangliomas detects SDH deficiency: clinical and pathophysiological implications.Neoplasia (New York, N.Y.) · 2015Article
- Potential therapeutic target for malignant paragangliomas: ATP synthase on the surface of paraganglioma cells.American journal of cancer research · 2015Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Warburg's metabolic hypothesis is based on the assumption that a cancer cell's respiration must be under attack, leading to its damage, in order to obtain increased glycolysis. Although this may not apply to all cancers, there is some evidence proving that primarily abnormally functioning mitochondrial complexes are indeed related to cancer development. Thus, mutations in complex II (succinate dehydrogenase (SDH)) lead to the formation of pheochromocytoma (PHEO)/paraganglioma (PGL). Mutations in one of the SDH genes (SDHx mutations) lead to succinate accumulation associated with very low fumarate levels, increased glutaminolysis, the generation of reactive oxygen species, and pseudohypoxia. This results in significant changes in signaling pathways (many of them dependent on the stabilization of hypoxia-inducible factor), including oxidative phosphorylation, glycolysis, specific expression profiles, as well as genomic instability and increased mutability resulting in tumor development. Although there is currently no very effective therapy for SDHx-related metastatic PHEOs/PGLs, targeting their fundamental metabolic abnormalities may provide a unique opportunity for the development of novel and more effective forms of therapy for these tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.